Post-Marketing Surveillance on Efficacy and Safety of Lomefloxacin (LOMEWON®) on Canine Bacterial Ocular Infection

Abstract

Clinical experience were surveyed regarding the safety and efficacy of LOMEWON®, 0.3% Lomefloxacin (LFLX) ophthalmic solution, for canine bacterial ocular infections. In addition, antibacterial effects of LFLX on S. intermedius, S. canis and P. aeruginosa were evaluated from 2005 to 2013. Among of 682 cases collected for the safety evaluation and the efficacy evaluation. Adverse drug reaction was observed in only one case, which was keratoconjunctivitis sicca. The rate of efficacy was 83.4% (569/682). The mean age was higher than that of participants to the clinical study (2001). The elderly dogs with keratitis had to treat longer period than younger dogs to heal with LOMEWON®. Recently, it has been recognized that prevalence of the isolates low-susceptible to LFLX. For that fact, vigorous treatment with the combination of several antibiotics, prior to detect the most effective drug, should be adopted in the commonly empiric therapy. It suggests that LOMEWON® is one of useful drug for the empiric therapy of canine ocular infections.